PRDM16 is associated with evasion of apoptosis by prostatic cancer cells according to RNA interference screening

Zhu,Shaoxing; Xu,Yipeng; Song,Mei; Chen,Guiping; Wang,Hua; Zhao,Yang; Wang,Zongping; Li,Fangyin

doi:10.3892/mmr.2016.5605

PRDM16 is associated with evasion of apoptosis by prostatic cancer cells according to RNA interference screening

Authors:
- Shaoxing Zhu
- Yipeng Xu
- Mei Song
- Guiping Chen
- Hua Wang
- Yang Zhao
- Zongping Wang
- Fangyin Li
View Affiliations

Affiliations: Department of Urology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China, Department of Ultrasonography, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China
Published online on: August 8, 2016 https://doi.org/10.3892/mmr.2016.5605
Pages: 3357-3361

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Histone methylation, which is regulated by histone methyltransferases (HMTs) and histone demethylases (HDMs), has been indicated to be involved in a variety of diseases, particularly in cancer, including androgen‑independent prostate cancer (PCa). However, the functions of HMTs and HDTs in cancer have largely remained elusive. The present study, utilized an RNA interference screening using a lentiviral small hairpin (sh)RNA library to systematically elucidate the function of HMTs and HDTs in PCa cell growth and viability. Nine HMTs and HDTs, namely FBXO11, PRDM10, JMJD8, MLL, SETD4, JMJD7, PRMT2, MEN1 and PRDM16, were identified to affect DU145 cell viability, as indicated by an MTS assay subsequent to knockdown of the specific genes using shRNA pools. Furthermore, flow cytometric analysis and western blot analysis of apoptosis‑associated proteins indicated that PRDM16 has an anti‑apoptotic role in PCa cells. In addition, the spliced form, sPRDM16/MEL1S, was detected to be overexpressed in PCa cell lines. In conclusion, the present study indicated an important oncogenic role of sPRDM16/MEL1S in PCa and suggested that PRDM16 may represent a novel therapeutic target.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Bert SA, Robinson MD, Strbenac D, Statham AL, Song JZ, Hulf T, Sutherland RL, Coolen MW, Stirzaker C and Clark SJ: Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer Cell. 23:9–22. 2013. View Article : Google Scholar
3	Coolen MW, Stirzaker C, Song JZ, Statham AL, Kassir Z, Moreno CS, Young AN, Varma V, Speed TP, Cowley M, et al: Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol. 12:235–246. 2010.PubMed/NCBI
4	Crea F, Sun L, Mai A, Chiang YT, Farrar WL, Danesi R and Helgason CD: The emerging role of histone lysine demethylases in prostate cancer. Mol Cancer. 11:522012. View Article : Google Scholar : PubMed/NCBI
5	Albert M and Helin K: Histone methyltransferases in cancer. Semin Cell Dev Biol. 21:209–220. 2010. View Article : Google Scholar
6	Shi Y, Lan F, Matson C, et al: Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1. Cell. 119:941–953. 2004. View Article : Google Scholar : PubMed/NCBI
7	Metzger E, Wissmann M, Yin N, Müller JM, Schneider R, Peters AH, Günther T, Buettner R and Schüle R: LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 437:436–439. 2005.PubMed/NCBI
8	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
9	Duan S, Cermak L, Pagan JK, Rossi M, Martinengo C, di Celle PF, Chapuy B, Shipp M, Chiarle R and Pagano M: FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature. 481:90–93. 2012. View Article : Google Scholar :
10	Baldwin RM, Morettin A, Paris G, Goulet I and Côté J: Alternatively spliced protein arginine methyltransferase 1 isoform PRMT1v2 promotes the survival and invasiveness of breast cancer cells. Cell Cycle. 11:4597–4612. 2012. View Article : Google Scholar : PubMed/NCBI
11	Paris PL, Sridharan S, Hittelman AB, Kobayashi Y, Perner S, Huang G, Simko J, Carroll P, Rubin MA and Collins C: An oncogenic role for the multiple endocrine neoplasia type 1 gene in prostate cancer. Prostate Cancer Prostatic Dis. 12:184–191. 2009. View Article : Google Scholar
12	Angelova S, Jordanova M, Spassov B, Shivarov V, Simeonova M, Christov I, Angelova P, Alexandrova K, Stoimenov A, Nikolova V, et al: Amplification of c-MYC and MLL genes as a marker of clonal cell progression in patients with myeloid malignancy and trisomy of chromosomes 8 or 11. Balkan J Med Genet. 14:17–24. 2011.PubMed/NCBI
13	Duhoux FP, Ameye G, Montano-Almendras CP, et al: PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. Br J Haematol. 156:76–88. 2012. View Article : Google Scholar
14	Faria JA, Corrêa NC, de Andrade C, et al: SET domain-containing protein 4 (SETD4) is a newly identified cytosolic and nuclear lysine methyltransferase involved in breast cancer cell proliferation. J Cancer Sci Ther. 5:58–65. 2013.PubMed/NCBI
15	Berry WL and Janknecht R: KDM4/JMJD2 histone demethylases: Epigenetic regulators in cancer cells. Cancer Res. 73:2936–2942. 2013. View Article : Google Scholar : PubMed/NCBI
16	Pinheiro I, Margueron R, Shukeir N, Eisold M, Fritzsch C, Richter FM, Mittler G, Genoud C, Goyama S, Kurokawa M, et al: Prdm3 and Prdm16 are H3K9me1 methyltransferases required for mammalian heterochromatin integrity. Cell. 150:948–960. 2012. View Article : Google Scholar : PubMed/NCBI
17	Yoshida M, Nosaka K, Yasunaga J, Nishikata I, Morishita K and Matsuoka M: Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells. Blood. 103:2753–2760. 2004. View Article : Google Scholar
18	Takahata M, Inoue Y, Tsuda H, Imoto I, Koinuma D, Hayashi M, Ichikura T, Yamori T, Nagasaki K, Yoshida M, et al: SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal in gastric cancer cells. J Biol Chem. 284:3334–3344. 2009. View Article : Google Scholar